New publication: Predictive validity in drug discovery

A key concern in pharmaceutical R&D is developing and using the best decision tools (e.g. models, assays) to advance disease knowledge and accurately assess therapeutic candidates. In the latest Perspectives review published recently in Nature Reviews Drug Discovery, Talisman Director, Dr. Mark Treherne and co-authors discuss the importance of predictive validity in drug discovery, showing how sensitive R&D productivity and cost-effectiveness are to this often-overlooked metric.

“…small improvements in aggregate predictive validity could be worth tens, perhaps hundreds, of millions of dollars per phase I candidate.”

Read the whole article for free here: Predictive validity in drug discovery: what it is, why it matters and how to improve it